PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,125 | -52.7% | 2,713 | -36.2% | 0.00% | – |
| Q2 2023 | $59,408 | +5410.9% | 4,251 | +2715.2% | 0.00% | – |
| Q1 2023 | $1,078 | -46.1% | 151 | +0.7% | 0.00% | – |
| Q4 2022 | $2,000 | -66.7% | 150 | -72.7% | 0.00% | – |
| Q3 2022 | $6,000 | -94.3% | 550 | -95.6% | 0.00% | – |
| Q2 2022 | $106,000 | -83.9% | 12,561 | -74.1% | 0.00% | -100.0% |
| Q1 2022 | $659,000 | +488.4% | 48,415 | +754.2% | 0.00% | – |
| Q4 2021 | $112,000 | +67.2% | 5,668 | +173.0% | 0.00% | – |
| Q3 2021 | $67,000 | +63.4% | 2,076 | +69.7% | 0.00% | – |
| Q2 2021 | $41,000 | -10.9% | 1,223 | 0.0% | 0.00% | – |
| Q1 2021 | $46,000 | +12.2% | 1,223 | 0.0% | 0.00% | – |
| Q4 2020 | $41,000 | -8.9% | 1,223 | 0.0% | 0.00% | – |
| Q3 2020 | $45,000 | +80.0% | 1,223 | +63.1% | 0.00% | – |
| Q2 2020 | $25,000 | – | 750 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |